Build or buy: How should new DTx players be developing their digital treatments?
Mobi Health News
FEBRUARY 12, 2021
MobiHealthNews spoke with Pear Therapeutics, Click Therapeutics and DTx newcomer Mahana Therapeutics to discuss whether in-licensing is the way to go for those just entering the space.
Let's personalize your content